Grigore Monica, Gresita Andrei, Hermann D M, Doeppner Thorsten R, Gheorman Victor, Glavan Daniela, Popa-Wagner Aurel
Department of Psychiatry, University of Medicine and Pharmacy Craiova, 200349, Craiova, Romania.
Chair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, Essen University Medical School, University of Duisburg-Essen, 45147, Essen, Germany.
J Neural Transm (Vienna). 2025 May;132(5):709-721. doi: 10.1007/s00702-025-02883-6. Epub 2025 Jan 30.
Attention-deficit/hyperactivity disorder (ADHD) is a frequently observed condition, with about 70% of individuals diagnosed with ADHD experiencing irregular sleep-wake patterns. Beyond the primary symptoms of ADHD, there is a significant overlap with sleep-related issues, indicating that disrupted sleep patterns may exacerbate ADHD symptoms. ADHD-related sleep problems can be traced to a delayed circadian rhythm and a later onset of melatonin production. Therefore, normalizing circadian rhythms has been proposed as a potential therapeutic target for psychiatric disorders. Recent animal studies have provided compelling evidence linking peroxisome proliferator-activated receptor gamma (PPARγ), a key regulator of energy metabolism, to the regulation of physiological and behavioral rhythms. In this study, we hypothesized that treating fibroblasts from ADHD patients, which exhibit disturbances in circadian rhythmicity that are replicated in peripheral fibroblasts, with rosiglitazone may restore their circadian rhythmicity to that of the controls. To this end, we used cultures of fibroblasts obtained from skin biopsy explants of ADHD patients and controls and investigated the temporal patterns of clock gene expression over a period of 24 h. We report that the administration of the PPARγ agonist, rosiglitazone significantly realigns the chronobiological patterns of ADHD patient samples and control groups by inducing phase shifts in the expression of the BMAL1, PER3, and CRY1 clock genes. Nevertheless, rosiglitazone showed limited impact on the amplitude and phase of CLOCK1, NPAS2, and PER1. No notable changes were observed in PER2 and PER3 gene expression. The data from cultured human dermal fibroblasts indicate that PPARγ-agonists may help regulate circadian molecular mechanisms. Given the shared genetic pathways between ADHD and obesity, future studies could investigate the potential of RSG as a treatment for circadian rhythm disorders, particularly in obese patients with ADHD.
注意力缺陷多动障碍(ADHD)是一种常见病症,约70%被诊断为ADHD的个体存在不规律的睡眠-觉醒模式。除了ADHD的主要症状外,还与睡眠相关问题存在显著重叠,这表明睡眠模式紊乱可能会加剧ADHD症状。与ADHD相关的睡眠问题可追溯到昼夜节律延迟和褪黑素分泌开始时间较晚。因此,使昼夜节律正常化已被提议作为精神疾病的一个潜在治疗靶点。最近的动物研究提供了令人信服的证据,将能量代谢的关键调节因子过氧化物酶体增殖物激活受体γ(PPARγ)与生理和行为节律的调节联系起来。在本研究中,我们假设用罗格列酮治疗ADHD患者的成纤维细胞(其昼夜节律紊乱在外周成纤维细胞中也有体现)可能会使其昼夜节律恢复到对照组的水平。为此,我们使用了从ADHD患者和对照组的皮肤活检外植体中获得的成纤维细胞培养物,并在24小时内研究了生物钟基因表达的时间模式。我们报告称,给予PPARγ激动剂罗格列酮可通过诱导BMAL1、PER3和CRY1生物钟基因表达的相位变化,显著重新调整ADHD患者样本和对照组的时间生物学模式。然而,罗格列酮对CLOCK1、NPAS2和PER1的振幅和相位影响有限。在PER2和PER3基因表达方面未观察到明显变化。来自培养的人真皮成纤维细胞的数据表明,PPARγ激动剂可能有助于调节昼夜分子机制。鉴于ADHD和肥胖之间存在共同的遗传途径,未来的研究可以探讨罗格列酮作为昼夜节律紊乱治疗方法的潜力,特别是在患有ADHD的肥胖患者中。